Cardiff Oncology to Showcase Onvansertib at Jefferies Healthcare Conference
Event summary
- Cardiff Oncology to present at Jefferies Global Healthcare Conference on June 4, 2026.
- CEO Mani Mohindru to lead fireside chat from 10:30-11:00 AM ET.
- Company developing onvansertib, a PLK1 inhibitor, for RAS-mutated metastatic colorectal cancer.
- Phase 2 trial ongoing for first-line treatment of mCRC.
- Investor meetings scheduled alongside conference participation.
The big picture
Cardiff Oncology's participation in the Jefferies conference comes as PLK1 inhibitors gain traction in precision oncology. The company's focus on RAS-mutated mCRC positions it in a high-unmet-need segment, though competition from broader-spectrum therapies remains a challenge. Success in Phase 2 could trigger strategic options, including potential out-licensing or acquisition discussions.
What we're watching
- Trial Momentum
- Whether Phase 2 data for onvansertib in mCRC will accelerate partnering discussions.
- Investor Sentiment
- How conference presentations impact Cardiff Oncology's valuation and investor confidence.
- Competitive Positioning
- The pace at which Cardiff Oncology can differentiate onvansertib in the crowded PLK1 inhibitor space.
Related topics